Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping
Overview
This synthesis provides a chronological mapping of disease progression across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). By aligning pathological events, biomarker changes, and clinical milestones, we can identify optimal therapeutic windows and biomarker screening opportunities.
This synthesis complements our [Disease Progression Staging Synthesis](/mechanisms/disease-progression-staging-synthesis), [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus), and [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis).
Conceptual Framework
Temporal Cascade Model
flowchart TD
subgraph Preclinical
A["Genetic Risk<br/>Factors"] --> B["Molecular<br/>Changes"]
B --> C["Cellular<br/>Dysfunction"]
C --> D["Subtle<br/>Biomarker Shifts"]
end
subgraph Prodromal
D --> E["Early Clinical<br/>Symptoms"]
E --> F["Biomarker<br/>Abnormalization"]
end
subgraph Clinical
F --> G["Established<br/>Disease"]
G --> H["Progressive<br/>Decline"]
H --> I["Advanced<br/>Stage"]
end
style Preclinical fill:#0a1f0a,stroke:#2e7d32,color:#e0e0e0
style Prodromal fill:#3e2200,stroke:#ef6c00,color:#e0e0e0
style Clinical fill:#2d0f0f,stroke:#c62828,color:#e0e0e0
Alzheimer's Disease Timeline
Preclinical Phase (10-20 years before symptoms)
...Disease Progression Timeline Synthesis — Neurodegenerative Disease Chronological Mapping
Overview
This synthesis provides a chronological mapping of disease progression across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). By aligning pathological events, biomarker changes, and clinical milestones, we can identify optimal therapeutic windows and biomarker screening opportunities.
This synthesis complements our [Disease Progression Staging Synthesis](/mechanisms/disease-progression-staging-synthesis), [Biomarker-Therapeutic Development Nexus](/mechanisms/biomarker-therapeutic-development-nexus), and [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis).
Conceptual Framework
Temporal Cascade Model
Mermaid diagram (expand to render)
Alzheimer's Disease Timeline
Preclinical Phase (10-20 years before symptoms)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -20 to -15 years | Aβ plaque initiation | CSF Aβ42 ↓, PET + | Highest — prevention trials |
| -15 to -10 years | Synaptic dysfunction | FDG-PET ↓, fMRI changes | High — synaptic protection |
| -10 to -5 years | Tau pathology begins | CSF p-tau181 ↑, PET + | Moderate — anti-tau |
| -5 to -2 years | Neurodegeneration starts | MRI atrophy, NfL ↑ | Lower — neuroprotection |
Prodromal Phase (MCI)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -2 to 0 years | Memory complaints | CDR 0.5, MMSE 24-30 | Moderate — disease modification |
| 0 to +1 years | Objective memory impairment | CSF Aβ/tau, volumetric MRI | Lower — symptomatic + DMT |
| +1 to +2 years | Functional decline begins | ADL scales affected | Limited — combination therapy |
Clinical Phase (Dementia)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +2 to +5 years | Mild-moderate dementia | CDR 1-2, MMSE 12-24 | Limited — symptomatic care |
| +5 to +10 years | Severe dementia | CDR 3, MMSE <12 | Palliative focus |
| +10+ years | Advanced disease | Total care required | Palliative focus |
Parkinson's Disease Timeline
Preclinical Phase (5-20 years before motor symptoms)
Per Braak staging (2003) and recent evidence:
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -20 to -10 years | Enteric nervous system involvement | α-syn in GI tract, p-S129 + | Highest — α-syn clearance |
| -10 to -5 years | Peripheral autonomic dysfunction | RBD, constipation, smell loss | High — neuroprotection |
| -5 to -2 years | Brainstem involvement | DaTscan changes, REM sleep behavior disorder | Moderate — disease modification |
| -2 to -1 years | Substantia nigra vulnerability | Motor prodromal markers | Lower — dopaminergic therapy |
Prodromal Phase
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -1 to 0 years | Subtle motor signs | UPDRS I-II, smell test | Moderate — early intervention |
| 0 to +1 years | Clinical diagnosis | UK Brain Bank criteria | Lower — symptomatic therapy |
| +1 to +3 years | Motor fluctuations begin | Levodopa response, DaTscan | Limited — optimization |
Clinical Phase
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +7 years | Motor complications | UPDRS III, dyskinesias | Limited — device therapy |
| +7 to +10 years | Advanced disease | Cognitive decline, falls | Palliative focus |
| +10+ years | Severe disability | Nursing home care | Palliative focus |
ALS Timeline
Preclinical Phase (unknown duration, possibly years)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| Unknown | Genetic mutation carriage | C9orf72, SOD1, FUS | Highest — preventive trials |
| Unknown | Epigenetic changes | DNA methylation patterns | High — epigenetic therapy |
| Unknown | Metabolic alterations | Creatinine, weight | Moderate — metabolic support |
Prodromal Phase (months to 1-2 years)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -12 to -6 months | Fasciculations, cramps | CK elevation, neurophysiology | Moderate — early intervention |
| -6 to 0 months | Subtle weakness | ALSFRS-R 48, grip strength | Lower — neuroprotection |
| 0 to +3 months | Progressive weakness | ALSFRS-R decline rate | Limited — symptomatic |
Clinical Phase
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +12 months | Progressive weakness | ALSFRS-R monthly decline | Limited — disease modification |
| +12 to +24 months | Respiratory involvement | FVC decline, bulbar | Palliative focus |
| +24+ months | Advanced disease | BiPAP, feeding tube | Palliative focus |
Frontotemporal Dementia Timeline
Preclinical Phase (10-15 years)
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -15 to -10 years | GRN/C9orf72/MAPT mutation | Genetic carrier | Highest — prevention trials |
| -10 to -5 years | Early brain atrophy | MRI, FDG-PET | High — disease modification |
| -5 to -2 years | Subtle behavior changes | Neuropsych testing | Moderate — early intervention |
Prodromal Phase
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| -2 to 0 years | Mild behavioral changes | FAB, CDR | Moderate — symptomatic |
| 0 to +1 years | FTD diagnosis | Clinical criteria | Lower — combination therapy |
| +1 to +3 years | Progressive deficits | ALSFRS-F, MRI | Limited |
Clinical Phase
| Timeline | Event | Biomarkers | Therapeutic Window |
|----------|-------|------------|-------------------|
| +3 to +7 years | Severe impairment | Total care | Palliative focus |
| +7+ years | Advanced disease | Terminal | Palliative focus |
Cross-Disease Biomarker Temporal Comparison
Blood Biomarker Changes Timeline
| Biomarker | AD | PD | ALS | FTD |
|-----------|:--:|:--:|:---:|:---:|
| p-tau181/217 | -10 years ↑ | — | — | — |
| NfL | -5 years ↑ | -2 years ↑ | -6 months ↑ | -2 years ↑ |
| α-synuclein (seed) | — | -10 years + | — | — |
| TDP-43 | — | — | -1 year + | -2 years + |
| Neurogranin | -10 years ↑ | — | — | — |
| BDNF | ↓ | ↓ | ↓ | ↓ |
Imaging Biomarker Timeline
| Modality | AD | PD | ALS | FTD |
|----------|:--:|:--:|:---:|:---:|
| Amyloid PET | -20 years + | — | — | — |
| Tau PET | -10 years + | — | — | — |
| DaTscan | — | -5 years ↓ | — | — |
| FDG-PET | -10 years ↓ | -5 years ↓ | -1 year ↓ | -5 years ↓ |
| MRI atrophy | -5 years | -2 years | -6 months | -2 years |
Therapeutic Window Analysis
Optimal Intervention Windows by Disease
| Phase | AD Target | PD Target | ALS Target | FTD Target |
|-------|-----------|------------|------------|------------|
| Preclinical | Anti-Aβ vaccination | α-synuclein clearance | Gene silencing | GRN restoration |
| Prodromal | Tau oligomer inhibition | Neuroprotection | Neuroprotection | TDP-43 modulation |
| Early Clinical | Synaptic preservation | Dopamine optimization | Respiratory support | Behavior management |
Cross-Disease Therapeutic Priorities
| Disease | Preclinical Window | Prodromal Window | Early Clinical Window |
|---------|-------------------|------------------|----------------------|
| AD | -20 to -10 years | -5 to 0 years | 0 to +5 years |
| PD | -20 to -5 years | -5 to 0 years | 0 to +7 years |
| ALS | Unknown | -1 to 0 years | 0 to +2 years |
| FTD | -15 to -5 years | -5 to 0 years | 0 to +7 years |
Clinical Trial Design Implications
Enrichment Strategies by Phase
| Disease | Preclinical Trial | Prodromal Trial | Early Clinical Trial |
|---------|-------------------|-----------------|----------------------|
| AD | Aβ+ cognitively normal | MCI-Aβ+ | MCI-AD, mild AD |
| PD | RBD, smell loss, genetic | Prodromal PD | Early PD, motor + |
| ALS | Gene carriers | Pre-symptomatic | Definite ALS |
| FTD | Mutation carriers | bvFTD prodromal | FTD spectrum |
Endpoint Considerations
- AD: CDR-SB, ADAS-Cog, PET amyloid/tau, CSF biomarkers
- PD: MDS-UPDRS, DaTscan, α-syn seed amplification assay
- ALS: ALSFRS-R, FVC, survival, NfL
- FTD: FAB, CDR, MRI volumetric, NfL
Knowledge Gaps
Preclinical duration variability: Unknown why some progress rapidly, others slowly
Biomarker temporal ordering: Exact sequence of biomarker changes unclear
Genetic modifier effects: How genetic variants modify timelines
Therapeutic window validation: When exactly interventions become ineffective
Cross-disease similarities: Shared progression patterns not fully mapped
Population-specific timelines: Ethnic/racial differences in progression
References
[Braak et al. Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://doi.org/10.1007/s00401-002-0620-9)
[Jack et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)](https://doi.org/10.1016/S1474-4422(10)70043-0)
[Chio et al. Global epidemiology of ALS - a systematic review (2019)](https://doi.org/10.1080/21678421.2019.1587768)
[Beach et al. Lewy body disease staging system for PD (2018)](https://doi.org/10.1002/mds.27313)
[Chen et al. Blood biomarkers across neurodegenerative diseases (2023)](https://doi.org/10.1038/s41582-023-00767-5)
[Preuss et al. ALS staging systems - clinical and biological correlates (2020)](https://doi.org/10.1002/amyot.2020.02.003)
[Hansson et al. Tau PET and amyloid PET in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)
[Postuma et al. Prodromal PD criteria (2019)](https://pubmed.ncbi.nlm.nih.gov/31734979/)
[Miller et al. FTD clinical criteria and staging (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Benatar et al. ALS prevention trials - challenges (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)